Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment
The significant growth in type 2 diabetes mellitus (T2DM) prevalence strikes a common threat to the healthcare and economic systems globally. Despite the availability of several anti-hyperglycaemic agents in the market, none can offer T2DM remission. These agents include the prominent incretin-based...
Saved in:
Main Authors: | Kok-Hou Lok (Author), Nicholas J. Wareham (Author), Rajesh Sreedharan Nair (Author), Chee Wun How (Author), Lay-Hong Chuah (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation
by: Cong Xie, et al.
Published: (2020) -
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
by: Yaochen Xie, et al.
Published: (2023) -
Tirzepatide - a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023) -
Enteroendocrine cells and gut hormones as potential targets in the crossroad of the gut-kidney axis communication
by: José Arimatéa de Oliveira Nery Neto, et al.
Published: (2023) -
Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport
by: Jennifer Lee, et al.
Published: (2017)